Analysis of clinical data has shown that glucose-lowering agents (GLP1 receptor agonists, SGLT2 inhibitors, metformin and DPP4 inhibitors) reduce the risk of dementia in patients with diabetes and that this neuroprotective effect is independent of weight loss [35]. This evidence concerns the gene SLC5A2 and dementia.